Tom Zhang

Tom Zhang

Auto-generated profile, based on publicly available information

Tom Zhang

Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TZTom Zhang
Tom Zhang
CAChristopher Febres Aldana
Christopher Febres Aldana
ZLZebing Liu
Zebing Liu
JDJenna-Marie Dix
Jenna-Marie Dix
RCRyan Cheng
Ryan Cheng
RSRomel Somwar
Romel Somwar
Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target. Experimental Design: ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays. Results: ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status. Conclusions: ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.

20 February 2025 in Cancer Discovery
Verified
Journal Article
Closed access
CAChristopher Febres Aldana
Christopher Febres Aldana
MVMorana Vojnic
Morana Vojnic
IOIgor Odintsov
Igor Odintsov
TZTom Zhang
Tom Zhang
RCRyan Cheng
Ryan Cheng
RSRomel Somwar
Romel Somwar
MET fusions (MET-F) are oncogenic drivers that remain poorly characterized. Analysis of 56 MET-F–positive tumors from an institutional cohort of 91,119 patients (79,864 DNA sequencing plus 11,255 RNA sequencing) uncovered two forms of MET-F pathobiology. The first group featured 5′ partners with homodimerization domains fused in-frame with the MET tyrosine kinase domain, primarily originated from translocations, frequently excluded MET exon 14, mediated oncogenesis through cytoplasmic aggregation and constitutive activation, and were markedly sensitive to MET tyrosine kinase inhibitors (TKI) in preclinical models and patients with lung cancer. The second group lacked partner homodimerization motifs and retained MET transmembrane and extracellular domains. Their pathogenesis involved intrachromosomal rearrangements, resulting in partner selection for promoter hijacking and fusion allele amplification. Membrane-bound fusions were enriched in gliomas with receptor tyrosine kinase co-alterations. We provide a framework to comprehend the heterogeneous landscape of MET-Fs, supporting that fusion oncogenicity and MET TKI sensitivity are determined by structural topology and pathogenomic context. Significance: MET fusions are primary drivers of tumor growth in multiple tumor types – lung cancer and gliomas – and can be effectively targeted with either type I (crizotinib, capmatinib, tepotinib, and savolitinib) or type II (cabozantinib) MET TKIs, with best responses in tumors harboring fusions with partner homodimerization.

16 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
APAlexander J. Pfeil
Alexander J. Pfeil
TZTom Zhang
Tom Zhang
RCRyan Cheng
Ryan Cheng
MMMarissa S. Mattar
Marissa S. Mattar
JMJuan Luis Gomez Marti
Juan Luis Gomez Marti
RSRomel Somwar
Romel Somwar
Purpose: RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS, HRAS, and NRAS. Whether homologous RRAS/RRAS2 mutations are oncogenic and actionable drivers in lung cancer remains underexplored. Experimental Design: An institutional cohort of 8,488 non–small cell lung carcinomas (NSCLC) sequenced by comprehensive targeted DNA sequencing (MSK-IMPACT) between 2016 and 2024 was evaluated for RRAS/RRAS2 mutations. RRASQ87L or RRAS2Q72L were modeled in murine IL3-dependent Ba/F3 cells and immortalized human bronchiolar epithelial cells (HBEC). The oncogenic potential, signaling characteristics, and sensitivity to MAPK pathway inhibitors, including the novel pan-RAS inhibitor RMC-6236, were evaluated in vitro and in vivo. Results: RRAS Q87L or RRAS2Q72L, homologous to KRAS-codon Q61 substitutions, were found in ∼0.45% of NSCLCs (38/8,488), with all but two lacking other MAPK pathway oncogenic drivers. RRASQ87L and RRAS2Q72L mutations transformed Ba/F3 cells and HBECs and robustly activated MAPK and PI3K–mTOR pathway signaling. RMC-6236 suppressed proliferation of RRASQ87L- and RRAS2Q72L-mutant cell lines, reduced ERK phosphorylation, induced apoptosis, and impeded cell-cycle progression. In vivo, RMC-6236 significantly inhibited growth of RRASQ87L/RRAS2Q72L-mutant HBEC-derived xenografts. Conclusions: RRASQ87L and RRAS2Q72L are recurrent, oncogenic, and potentially actionable drivers in NSCLC. Our study supports the inclusion of RRAS/RRAS2 into routine molecular diagnostic panels for precision oncology and provides preclinical rationale for investigating the potential therapeutic utility of pan-RAS inhibitors for patients with RRASQ87L/RRAS2Q72L-mutant lung cancers.

15 October 2024
Verified
Other
Open access
TZTom Zhang
Tom Zhang
CAChristopher Febres Aldana
Christopher Febres Aldana
ZLZebing Liu
Zebing Liu
JDJenna-Marie Dix
Jenna-Marie Dix
RCRyan Cheng
Ryan Cheng
RSRomel Somwar
Romel Somwar
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor